Cipla
Last updated Jun 20, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
69%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Hematology
- Multiple Myeloma
- Respiratory
- Bronchodilator
- Psychiatry
Highest priority development: FDA TA — CANAGLIFLOZIN (ORIG)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Cipla; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 69%
Active Signals
9
Investigate Priority
0
Opportunity Score
464
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 20, 2026Score 53FDA Approves Albuterol Sulfate ANDA219409 from Cipla
Respiratory · Bronchodilator
- MonitorJul 15, 2026Score 52Phase II Trial of Pramipexole vs Escitalopram for MDD in HIV Patients
Psychiatry · Major Depressive Disorder
- MonitorJul 7, 2026Score 52Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA
Oncology · Multiple Myeloma
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA TA — CANAGLIFLOZIN (ORIG)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — BUPROPION HYDROCHLORIDE (ORIG)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — NEURACEQ (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — CHILDREN'S MOTRIN (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Cipla right now?
- Which regulatory precedents should Cipla monitor in Hematology and Multiple Myeloma?
- Which pipeline programs should Cipla prioritize for competitive review?
- What signals require immediate investigation for Cipla?
- Summarize the strategic implications of recent developments for Cipla.
- Where is the greatest uncertainty in Cipla's competitive positioning?